Spike Protein News and Research

RSS

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Researchers tested the vaccine candidate in mice with up to three doses and found it produces high levels of antibodies against both SARS-CoV-2 variants of concern and the original virus strain.

20 May 2021

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

A new research paper posted to the preprint server medRxiv* reports the rise of a new lineage in Tokyo, Japan, bearing a combination of two biologically important mutations.

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Researchers from Israel recently isolated a set of SARS-CoV-2 neutralizing monoclonal antibodies from blood samples of patients with severe COVID-19. They were the first to show that transgenic K18-hACE2 mice infected with lethal doses of SARS-CoV-2 can be fully protected by administering antibodies even 3 days after infection

19 May 2021

Researchers use base editing to sustainably lower high LDL cholesterol levels

Base editing is a novel gene editing approach that can precisely change individual building blocks in a DNA sequence.

19 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A preprint discusses the results of a study of antibody responses to the first and second dose of currently available SARS-CoV-2 vaccines, Pfizer and Oxford.

19 May 2021

To the bat cave: In search of covid’s origins, scientists reignite polarizing debate on Wuhan ‘lab leak’

Once dismissed as a conspiracy theory, the idea that the covid virus escaped from a Chinese lab is gaining high-profile attention. As it does, reputations of renowned scientists are at risk — and so is their personal safety.

19 May 2021

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

India’s surge in SARS-CoV-2 infections are linked to the new variants B.1.617 and B.1.618, with mutated spike proteins.

19 May 2021

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Sequentia Biotech and NextBiomics announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome.

From Sequentia Biotech 19 May 2021

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

New research published on the preprint server bioRxiv* performed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic simulations to understand the evolutionary transition from a bat-adapted SARS-CoV-2 to a human-adapted virus.

19 May 2021

Study identifies mechanism behind SARS-CoV-2 fusion of host cells

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mediated by the fusion of the spike protein to nearby healthy cells. New research by German researchers sheds light on how this happens.

19 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Researchers from Germany and the USA recently investigated the cellular and humoral immune responses of patients with IMIDs on immunomodulatory treatment to mRNA COVID-19 vaccines. The research is published on the medRxiv* preprint server.

19 May 2021

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

In a new study, researchers used an antibody discovery technology to identify a new potently neutralizing antibody with a unique mode of SARS-CoV-2 recognition. They reported their results on the bioRxiv preprint server.

18 May 2021

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

A study of immune-deficient adults and children has shown that patients who fail to respond positively to infections and vaccinations have robust humoral immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) structural proteins.

18 May 2021

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Researchers discovered the first N440K variant and the new E484Q and L452R Indian variants isolated in France in a recent study. They presented the genetic mutations in the isolated genomes and the phylogenetic tree, including these strains among different SARS-CoV-2 clades. This work is posted on the bioRxiv preprint server.

18 May 2021

SpaceX study profiles evolution of antibody response during COVID-19 infection

New research published on the preprint server bioRxiv* suggests S2-specific antibody responses are critical in recovering from mild to severe COVID-19 infection. Compared to patients who died within 28 days of their COVID-19 diagnosis, patients who produced a wide range of S2-specific responses were more likely to survive.

18 May 2021

Spike Protein News and Research

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Researchers use base editing to sustainably lower high LDL cholesterol levels

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Spike antibodies after vaccination with Pfizer and Oxford vaccines

To the bat cave: In search of covid’s origins, scientists reignite polarizing debate on Wuhan ‘lab leak’

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

Study identifies mechanism behind SARS-CoV-2 fusion of host cells

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

SpaceX study profiles evolution of antibody response during COVID-19 infection

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News